Lipid Nanocarriers for Hyperproliferative Skin Diseases
CEB—Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal
Faculty of Pharmaceutical Sciences, São Paulo State University (UNESP), Campus of Araraquara, Rodovia Araraquara Jaú, Araraquara 14800-903, SP, Brazil
Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08007 Barcelona, Spain
Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08007 Barcelona, Spain
Institute of Human Genetics, Polish Academy of Sciences, Strzeszyńska 32, 60-479 Poznań, Poland
Department of Hypertension Angiology and Internal Medicine, Poznań University of Medical Sciences, 61-701 Poznań, Poland
Department of Environmental Medicine, Poznań University of Medical Sciences, 61-701 Poznań, Poland
Department of Gastroenterology, Dietetics and Internal Diseases, H. Swiecicki University Hospital, Poznań University of Medical Sciences, 60-355 Poznań, Poland
Authors to whom correspondence should be addressed.
Academic Editors: Maciej Wnuk and Anna Lewinska
Received: 6 October 2021
Revised: 5 November 2021
Accepted: 5 November 2021
Published: 10 November 2021
Different drugs, including antiproliferative and corticosteroids in general, are recommended for the treatment of hyperproliferative skin diseases (HSD). The effectiveness of many of these drugs is limited due to their low solubility in water and low penetration in the skin. The loading of these drugs in lipid nanocarriers, such as lipid nanoparticles and liposomes, has been considered as a successful solution to improve the drug bioavailability through the skin, to control their release kinetics and thus reduce the risk of potential side effects. In this work, we discuss the use of lipid nanocarriers loading drugs against HSD.